Crossject SA, a French company with a needle-free pharmaceutical injection system designed for self-administration, is issuing 1,538,462 shares in an initial public offering on the NYSE Alternext exchange in Paris. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
